Edwards Lifesciences Corporation (ETR:EWL)

Market Cap	42.68B
Revenue (ttm)	5.01B
Net Income (ttm)	1.17B
Shares Out	n/a
EPS (ttm)	1.99
PE Ratio	36.61
Forward PE	31.02
Dividend	n/a
Ex-Dividend Date	n/a

Volume	123
Average Volume	37
Open	71.40
Previous Close	72.71
Day's Range	71.40 - 73.12
52-Week Range	59.30 - 76.02
Beta	n/a
RSI	63.58
Earnings Date	Feb 13, 2026

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband brands. It also provides surgical structural heart solution...

• Industry: Orthopedic, Prosthetic, and Surgical Appliances and Supplies
• Founded: 1958
• Employees: 15,800
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EWL

Financial Performance

In 2024, Edwards Lifesciences's revenue was $5.44 billion, an increase of 8.57% compared to the previous year's $5.01 billion. Earnings were $4.17 billion, an increase of 197.68%.

Financial numbers in USD